Abbvie Biotechnology Ltd

Rebecca S Hoffman

Elliot Keith Chartash

George Richard Granneman

Lori K Taylor

Philip Yan

Mark Weinberg

Jochen G Salfeld

Steven Alan Fischkoff

Subhashis Banerjee

Daniel Edward Tracey

Lynne E Rueter

Anwar Murtaza

William T Barchuk

Clive E Spiegler

John R Medich

Robert L Wong

Christopher T Ritchlin

Martin M Okun

Renee J Perdok

Jonathan Barker

Phillip Mease

Eric H Sasso

Michael W Decker

Walid M Abi-saab

Ana M Basso

Elliot Chartash

Steven Fischkoff

Eliot Keith Chartash

The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF&#x3b1; inhibitor, such as a human TNF&#x3b1; antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF&#x3b1; inhibitor for treatment of psoriatic arthritis in a subject.

Uses and compositions for treatment of psoriatic arthritis

The invention provides methods and compositions for the treatment of a skin disorder associated with detrimental TNF&#x3b1; activity, such as psoriasis. The invention includes methods for treating a skin disorder associated with detrimental TNF&#x3b1; activity, such as psoriasis, in a subject who has failed or lost response to prior biologic therapy, such as prior administration of etanercept. The invention further provides methods for determining the efficacy of a human TNF&#x3b1; antibody, or antigen-binding portion thereof, for the treatment of a skin disorder associated with detrimental TNF&#x3b1; activity, such as psoriasis.

Methods and compositions for treatment of skin disorders

The invention describes methods of treating erosive polyarthritis comprising administering a TNF&#x3b1; antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF&#x3b1; antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.

Use of TNF&#x3b1; inhibitor

Multiple-variable dose methods for treating TNF&#x3b1;-related disorders, including Crohn's disease and psoriasis, comprising administering TNF&#x3b1; inhibitors, including TNF&#x3b1; antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.

Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease

Growing community of inventors

Wilmette, IL, United States of America

Rebecca S Hoffman